The prognostic value of a positive ctDNA test in urothelial cancer intensifies throughout the treatment journey. Failure to clear ctDNA after neoadjuvant therapy and then surgery is associated with a dramatically increasing hazard ratio for death, signaling profound treatment failure.

Data from trials like Niagara suggests a powerful new paradigm for assessing treatment success. Combining urine tumor DNA (uTDNA) for local disease and circulating tumor DNA (ctDNA) for systemic relapse offers a more dynamic view than traditional pathology and is poised to become the superior surrogate endpoint in bladder cancer trials.

Circulating tumor DNA (ctDNA) is a powerful tool in bladder cancer. A positive result post-surgery is a strong indicator for initiating adjuvant therapy. However, a negative result does not guarantee a cure, as a notable percentage of these patients still relapse, making clinicians cautious about withholding treatment based on a single negative test.

Circulating tumor DNA (ctDNA) is a powerful biomarker for identifying high-risk bladder cancer patients. However, its imperfection presents a new clinical dilemma: with a ~12% relapse rate even in ctDNA-negative patients, clinicians must decide whether to withhold adjuvant therapy and accept that risk, or overtreat the 88% who are likely cured.

The future of bladder cancer surveillance may involve using two types of liquid biopsies in tandem. A patient who is utDNA-positive but ctDNA-negative likely has a local, primary bladder issue. Conversely, a utDNA-negative but ctDNA-positive result suggests the cancer has already spread systemically, providing crucial information for treatment planning.

In adjuvant bladder cancer trials, ctDNA status is both prognostic and predictive. Patients with positive ctDNA after surgery are at high risk of relapse but benefit from immune checkpoint inhibitors. Conversely, ctDNA-negative patients have a lower risk and derive no benefit, making ctDNA a critical tool to avoid unnecessary, toxic therapy.

Beyond a simple positive/negative result, the quantitative level of ctDNA is highly prognostic in bladder cancer. Similar to PSA in prostate cancer, higher ctDNA levels correlate with a significantly worse prognosis, offering a more nuanced risk assessment tool than a binary test.

Experts suggest urinary tumor DNA (utDNA) may better reflect local disease in the bladder, while circulating tumor DNA (ctDNA) indicates systemic disease. Using both tests in parallel could provide a more complete picture, with dual-negative results potentially becoming a key criterion for safely pursuing bladder-sparing approaches.

Across multiple recent trials, a consistent finding is that if a bladder cancer patient's circulating tumor DNA (ctDNA) does not clear after treatment, it is an extremely poor prognostic sign. This strong signal suggests that these patients should likely be switched to a different therapeutic approach immediately.